Lamotrigine (All indications)

Gestational diabetes

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8904
R30085		 Aydin (Lamotrigine), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 1.05 [0.04;29.08] C 0/7   1/22 1 7
ref
S12465
R46888		 Galbally, 2020 Gestational diabetes mellitus (GDM) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 1.21 [0.26;5.73] C 2/19   16/181 18 19
ref
S8952
R30264		 Rihtman (Lamotrigine), 2013 Mothers: gestational diabetes in pregnancy at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 1.28 [0.02;65.87] C 0/40   0/51 0 40
ref
Total 3 studies 1.19 [0.32;4.49] 19 66
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Lamotrigine), 2020Aydin, 2020 1 1.05[0.04; 29.08]1716%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Galbally, 2020Galbally, 2020 1.21[0.26; 5.73]181973%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Rihtman (Lamotrigine), 2013Rihtman, 2013 2 1.28[0.02; 65.87]04011%ROB confusion: moderateROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.19[0.32; 4.49]19660.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine; 2: Lamotrigine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.19[0.32; 4.49]19660%NAAydin (Lamotrigine), 2020 Galbally, 2020 Rihtman (Lamotrigine), 2013 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.28[0.02; 65.87]-40 -NARihtman (Lamotrigine), 2013 1 unexposed, sickunexposed, sick 1.18[0.29; 4.83]19260%NAAydin (Lamotrigine), 2020 Galbally, 2020 2 Tags Adjustment   - No  - No 1.19[0.32; 4.49]19660%NAAydin (Lamotrigine), 2020 Galbally, 2020 Rihtman (Lamotrigine), 2013 3 All studiesAll studies 1.19[0.32; 4.49]19660%NAAydin (Lamotrigine), 2020 Galbally, 2020 Rihtman (Lamotrigine), 2013 30.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.28[0.02; 65.87]-40 -NARihtman (Lamotrigine), 2013 1 unexposed, sick controlsunexposed, sick controls 1.18[0.29; 4.83]19260%NAAydin (Lamotrigine), 2020 Galbally, 2020 20.510.01.0